Carlo Brugnara

Publications

1. 17(R)-RESOLVIN D1 PROTECTS AGAINST SICKLE CELL-RELATED INFLAMMATORY CARDIOMYOPATHY IN HUMANIZED MICE. Blood. 2025 Feb 10. View Abstract
2. Biomechanics of phagocytosis of red blood cells by macrophages in the human spleen. Proc Natl Acad Sci U S A. 2024 Oct 29; 121(44):e2414437121. View Abstract
3. Self-pay laboratory charges for iron deficiency diagnosis in the Boston and New Haven metropolitan areas. Am J Hematol. 2024 Nov; 99(11):2233-2235. View Abstract
4. Hematology Laboratory in the Digital and Automation Age. Clin Lab Med. 2024 Sep; 44(3):xiii-xiv. View Abstract
5. Epeleuton, a novel synthetic ?-3 fatty acid, reduces hypoxia/ reperfusion stress in a mouse model of sickle cell disease. Haematologica. 2024 06 01; 109(6):1918-1932. View Abstract
6. Acute Promyelocytic Leukemia With Torque Teno Mini Virus::RARA Fusion: An Approach to Screening and Diagnosis. Mod Pathol. 2024 Jul; 37(7):100509. View Abstract
7. Nrf2 Plays a Key Role in Erythropoiesis during Aging. Antioxidants (Basel). 2024 Apr 12; 13(4). View Abstract
8. Mitapivat reprograms the RBC metabolome and improves anemia in a mouse model of hereditary spherocytosis. JCI Insight. 2023 10 23; 8(20). View Abstract
9. Mitapivat, a pyruvate kinase activator, improves transfusion burden and reduces iron overload in ß-thalassemic mice. Haematologica. 2023 09 01; 108(9):2535-2541. View Abstract
10. Immune therapies in the treatment of multiple myeloma. Am J Hematol. 2023 03; 98 Suppl 2:S3. View Abstract
11. Variation and impact of polygenic hematologic traits in monogenic sickle cell disease. Haematologica. 2023 03 01; 108(3):870-881. View Abstract
12. In Humanized Sickle Cell Mice, Imatinib Protects Against Sickle Cell-Related Injury. Hemasphere. 2023 Mar; 7(3):e848. View Abstract
13. Immune Therapies in the Treatment of Multiple Myeloma. Am J Hematol. 2023 Jan 19. View Abstract
14. HbSC disease: A time for progress. Am J Hematol. 2022 11; 97(11):1390-1393. View Abstract
15. The erythroid K-Cl cotransport inhibitor [(dihydroindenyl)oxy]acetic acid blocks erythroid Ca2+-activated K+ channel KCNN4. Am J Physiol Cell Physiol. 2022 09 01; 323(3):C694-C705. View Abstract
16. The Erythrocyte, a Novel Disease-Mediator for COVID-19 Vasculopathy? JACC Basic Transl Sci. 2022 Mar; 7(3):205-206. View Abstract
17. Erythroid-specific inactivation of Slc12a6/Kcc3 by EpoR promoter-driven Cre expression reduces K-Cl cotransport activity in mouse erythrocytes. Physiol Rep. 2022 03; 10(5):e15186. View Abstract
18. Commentaries on Viewpoint: Consider iron status when making sex comparisons in human physiology. J Appl Physiol (1985). 2022 03 01; 132(3):703-709. View Abstract
19. Purinergic signaling is essential for full Psickle activation by hypoxia and by normoxic acid pH in mature human sickle red cells and in vitro-differentiated cultured human sickle reticulocytes. Pflugers Arch. 2022 05; 474(5):553-565. View Abstract
20. Trpv1 and Trpa1 are not essential for Psickle-like activity in red cells of the SAD mouse model of sickle cell disease. Blood Cells Mol Dis. 2021 12; 92:102619. View Abstract
21. Standardization of reticulocyte counts in the athlete biological passport: A practical update. Int J Lab Hematol. 2022 Feb; 44(1):112-117. View Abstract
22. Diagnostics with modern genomics. Am J Hematol. 2021 11 01; 96(11):E447. View Abstract
23. A Grammastola spatulata mechanotoxin-4 (GsMTx4)-sensitive cation channel mediates increased cation permeability in human hereditary spherocytosis of multiple genetic etiologies. Haematologica. 2021 10 01; 106(10):2759-2762. View Abstract
24. An artificial intelligence-assisted diagnostic platform for rapid near-patient hematology. Am J Hematol. 2021 10 01; 96(10):1264-1274. View Abstract
25. Global genome analysis reveals a vast and dynamic anellovirus landscape within the human virome. Cell Host Microbe. 2021 Aug 11; 29(8):1305-1315.e6. View Abstract
26. Dietary ?-3 Fatty Acid Supplementation Improves Murine Sickle Cell Bone Disease and Reprograms Adipogenesis. Antioxidants (Basel). 2021 May 18; 10(5). View Abstract
27. The pyruvate kinase activator mitapivat reduces hemolysis and improves anemia in a ß-thalassemia mouse model. J Clin Invest. 2021 05 17; 131(10). View Abstract
28. Using Reticulocyte Hemoglobin Equivalent as a Marker for Iron Deficiency and Responsiveness to Iron Therapy. Mayo Clin Proc. 2021 06; 96(6):1510-1519. View Abstract
29. Haematological effects of oral administration of bitopertin, a glycine transport inhibitor, in patients with non-transfusion-dependent ß-thalassaemia. Br J Haematol. 2021 07; 194(2):474-477. View Abstract
30. Single-cell analysis of FOXP3 deficiencies in humans and mice unmasks intrinsic and extrinsic CD4+ T cell perturbations. Nat Immunol. 2021 05; 22(5):607-619. View Abstract
31. Less (Fe) is more (Hb) in SCA. Blood. 2021 03 18; 137(11):1446-1447. View Abstract
32. Plasmodium vivax infection compromises reticulocyte stability. Nat Commun. 2021 03 12; 12(1):1629. View Abstract
33. Haemoglobin response to senicapoc in patients with sickle cell disease: a re-analysis of the Phase III trial. Br J Haematol. 2021 03; 192(5):e129-e132. View Abstract
34. Potential causal role of l-glutamine in sickle cell disease painful crises: A Mendelian randomization analysis. Blood Cells Mol Dis. 2021 02; 86:102504. View Abstract
35. Pediatric hematology normal ranges derived from pediatric primary care patients. Am J Hematol. 2020 Oct; 95(10):E255-E257. View Abstract
36. Association of Blood Type With Postsurgical Mucosal Bleeding in Pediatric Patients Undergoing Tonsillectomy With or Without Adenoidectomy. JAMA Netw Open. 2020 03 02; 3(3):e201804. View Abstract
37. Non-Parametric Combined Reference Regions and Prediction of Clinical Risk. Clin Chem. 2020 02 01; 66(2):363-372. View Abstract
38. Corrigendum to "Combined genetic disruption of K-Cl cotransporters and Gardos channel KCNN4 rescues erythrocyte dehydration in the SAD mouse model of sickle cell disease" [Blood Cells Mol. Dis. (2019) start page-end page not yet assigned] https://doi.org/10.1016/j.bcmd.2019.102346. Blood Cells Mol Dis. 2020 Mar; 81:102390. View Abstract
39. Genetic disruption of KCC cotransporters in a mouse model of thalassemia intermedia. Blood Cells Mol Dis. 2020 03; 81:102389. View Abstract
40. Bitopertin, a selective oral GLYT1 inhibitor, improves anemia in a mouse model of ß-thalassemia. JCI Insight. 2019 11 14; 4(22). View Abstract
41. Combined genetic disruption of K-Cl cotransporters and Gardos channel KCNN4 rescues erythrocyte dehydration in the SAD mouse model of sickle cell disease. Blood Cells Mol Dis. 2019 11; 79:102346. View Abstract
42. Monitoring of blood coagulation with non-contact drop oscillation rheometry. J Thromb Haemost. 2019 08; 17(8):1345-1353. View Abstract
43. Erythrocyte ion content and dehydration modulate maximal Gardos channel activity in KCNN4 V282M/+ hereditary xerocytosis red cells. Am J Physiol Cell Physiol. 2019 08 01; 317(2):C287-C302. View Abstract
44. Highly efficient therapeutic gene editing of human hematopoietic stem cells. Nat Med. 2019 May; 25(5):776-783. View Abstract
45. Heritability of fetal hemoglobin, white cell count, and other clinical traits from a sickle cell disease family cohort. Am J Hematol. 2019 05; 94(5):522-527. View Abstract
46. Shape oscillations of single blood drops: applications to human blood and sickle cell disease. Sci Rep. 2018 11 14; 8(1):16794. View Abstract
47. Resolution of sickle cell disease-associated inflammation and tissue damage with 17R-resolvin D1. Blood. 2019 01 17; 133(3):252-265. View Abstract
48. Increased Red Cell KCNN4 Activity in Sporadic Hereditary Xerocytosis Associated With Enhanced Single Channel Pressure Sensitivity of PIEZO1 Mutant V598M. Hemasphere. 2018 10; 2(5):e55. View Abstract
49. Genotype-phenotype correlation and risk stratification in a cohort of 123 hereditary stomatocytosis patients. Am J Hematol. 2018 12; 93(12):1509-1517. View Abstract
50. A common functional PIEZO1 deletion allele associates with red blood cell density in sickle cell disease patients. Am J Hematol. 2018 11; 93(11):E362-E365. View Abstract
51. Erythrocytes lacking the Langereis blood group protein ABCB6 are resistant to the malaria parasite Plasmodium falciparum. Commun Biol. 2018; 1:45. View Abstract
52. Positive Iron Balance in Chronic Kidney Disease: How Much is Too Much and How to Tell? Am J Nephrol. 2018; 47(2):72-83. View Abstract
53. Sickle cell dehydration: Pathophysiology and therapeutic applications. Clin Hemorheol Microcirc. 2018; 68(2-3):187-204. View Abstract
54. Iron balance and iron supplementation for the female athlete: A practical approach. Eur J Sport Sci. 2018 Mar; 18(2):295-305. View Abstract
55. Knowledge of Blood Group Decreases von Willebrand Factor Panel Testing in Children. Hemasphere. 2017 12; 1(1):e3. View Abstract
56. Revised prevalence estimate of possible Hereditary Xerocytosis as derived from a large U.S. Laboratory database. Am J Hematol. 2018 01; 93(1):E9-E12. View Abstract
57. Automated cell counts on CSF samples: A multicenter performance evaluation of the GloCyte system. Int J Lab Hematol. 2018 Feb; 40(1):56-65. View Abstract
58. Genome-wide association study of erythrocyte density in sickle cell disease patients. Blood Cells Mol Dis. 2017 06; 65:60-65. View Abstract
59. Erythrocytes from hereditary xerocytosis patients heterozygous for KCNN4 V282M exhibit increased spontaneous Gardos channel-like activity inhibited by senicapoc. Am J Hematol. 2017 06; 92(6):E108-E110. View Abstract
60. Variant-aware saturating mutagenesis using multiple Cas9 nucleases identifies regulatory elements at trait-associated loci. Nat Genet. 2017 Apr; 49(4):625-634. View Abstract
61. Diagnosis of iron deficiency anemia using density-based fractionation of red blood cells. Lab Chip. 2016 10 05; 16(20):3929-3939. View Abstract
62. Functional characterization of novel ABCB6 mutations and their clinical implications in familial pseudohyperkalemia. Haematologica. 2016 08; 101(8):909-17. View Abstract
63. The American Journal of Hematology turns 40. Am J Hematol. 2016 Jan; 91(1):4. View Abstract
64. Targeted Application of Human Genetic Variation Can Improve Red Blood Cell Production from Stem Cells. Cell Stem Cell. 2016 Jan 07; 18(1):73-78. View Abstract
65. The Clinically Tested Gardos Channel Inhibitor Senicapoc Exhibits Antimalarial Activity. Antimicrob Agents Chemother. 2016 01; 60(1):613-6. View Abstract
66. 2015 Clinical trials update in sickle cell anemia. Am J Hematol. 2015 Oct; 90(10):934-50. View Abstract
67. Novel Gardos channel mutations linked to dehydrated hereditary stomatocytosis (xerocytosis). Am J Hematol. 2015 Oct; 90(10):921-6. View Abstract
68. Diagnosis of iron-deficient states. Crit Rev Clin Lab Sci. 2015; 52(5):256-72. View Abstract
69. Diagnosis of iron-deficient states. Crit Rev Clin Lab Sci. 2015 Aug 14; 1-17. View Abstract
70. Rapamycin improves TIE2-mutated venous malformation in murine model and human subjects. J Clin Invest. 2015 Sep; 125(9):3491-504. View Abstract
71. Malaria. A forward genetic screen identifies erythrocyte CD55 as essential for Plasmodium falciparum invasion. Science. 2015 May 08; 348(6235):711-4. View Abstract
72. Dietary ?-3 fatty acids protect against vasculopathy in a transgenic mouse model of sickle cell disease. Haematologica. 2015 Jul; 100(7):870-80. View Abstract
73. The utility of the DDAVP challenge test in children with low von Willebrand factor. Br J Haematol. 2015 Sep; 170(6):884-6. View Abstract
74. American Journal of Hematology, getting ready for the 40th birthday in 2016. Am J Hematol. 2015 Jan; 90(1):1. View Abstract
75. Reductions in red blood cell 2,3-diphosphoglycerate concentration during continuous renal replacment therapy. Clin J Am Soc Nephrol. 2015 Jan 07; 10(1):74-9. View Abstract
76. Evaluation of a density-based rapid diagnostic test for sickle cell disease in a clinical setting in Zambia. PLoS One. 2014; 9(12):e114540. View Abstract
77. Automated hematology analyzers: state of the art. Clin Lab Med. 2015 Mar; 35(1):xiii-xiv. View Abstract
78. Clinical utility of reticulocyte parameters. Clin Lab Med. 2015 Mar; 35(1):133-63. View Abstract
79. Optical assay of erythrocyte function in banked blood. Sci Rep. 2014 Sep 05; 4:6211. View Abstract
80. Density-based separation in multiphase systems provides a simple method to identify sickle cell disease. Proc Natl Acad Sci U S A. 2014 Oct 14; 111(41):14864-9. View Abstract
81. FOXO3-mTOR metabolic cooperation in the regulation of erythroid cell maturation and homeostasis. Am J Hematol. 2014 Oct; 89(10):954-63. View Abstract
82. Hereditary xerocytosis revisited. Am J Hematol. 2014 Dec; 89(12):1142-6. View Abstract
83. Aging-like phenotype and defective lineage specification in SIRT1-deleted hematopoietic stem and progenitor cells. Stem Cell Reports. 2014 Jul 08; 3(1):44-59. View Abstract
84. Alpha-thalassaemia and response to hydroxyurea in sickle cell anaemia. Eur J Haematol. 2014 Apr; 92(4):341-5. View Abstract
85. Resveratrol accelerates erythroid maturation by activation of FoxO3 and ameliorates anemia in beta-thalassemic mice. Haematologica. 2014 Feb; 99(2):267-75. View Abstract
86. Dehydrated stomatocytic anemia due to the heterozygous mutation R2456H in the mechanosensitive cation channel PIEZO1: a case report. Blood Cells Mol Dis. 2014 Jan; 52(1):53-4. View Abstract
87. Red cell indices in classification and treatment of anemias: from M.M. Wintrobes's original 1934 classification to the third millennium. Curr Opin Hematol. 2013 May; 20(3):222-30. View Abstract
88. Strain-specific variations in cation content and transport in mouse erythrocytes. Physiol Genomics. 2013 May 01; 45(9):343-50. View Abstract
89. Multiple clinical forms of dehydrated hereditary stomatocytosis arise from mutations in PIEZO1. Blood. 2013 May 09; 121(19):3925-35, S1-12. View Abstract
90. Expansion of host cellular niche can drive adaptation of a zoonotic malaria parasite to humans. Nat Commun. 2013; 4:1638. View Abstract
91. Missense mutations in the ABCB6 transporter cause dominant familial pseudohyperkalemia. Am J Hematol. 2013 Jan; 88(1):66-72. View Abstract
92. Calpain-1 knockout reveals broad effects on erythrocyte deformability and physiology. Biochem J. 2012 Nov 15; 448(1):141-52. View Abstract
93. Iron deficiency: what are the future trends in diagnostics and therapeutics? Clin Chem. 2013 May; 59(5):740-5. View Abstract
94. Mitochondrial Atpif1 regulates haem synthesis in developing erythroblasts. Nature. 2012 Nov 22; 491(7425):608-12. View Abstract
95. Pharmacological inhibition of calpain-1 prevents red cell dehydration and reduces Gardos channel activity in a mouse model of sickle cell disease. FASEB J. 2013 Feb; 27(2):750-9. View Abstract
96. Erythrocyte density in sickle cell syndromes is associated with specific clinical manifestations and hemolysis. Blood. 2012 Oct 11; 120(15):3136-41. View Abstract
97. Oxygen gas-filled microparticles provide intravenous oxygen delivery. Sci Transl Med. 2012 Jun 27; 4(140):140ra88. View Abstract
98. An appeal to medical journal editors: the need for a full description of laboratory methods and specimen handling in clinical study reports. Am J Hematol. 2012 Apr; 87(4):347-8. View Abstract
99. An appeal to medical journal editors: the need for a full description of laboratory methods and specimen handling in clinical study reports. Transfusion. 2012 Jun; 52(6):e17-9. View Abstract
100. An appeal to medical journal editors: the need for a full description of laboratory methods and specimen handling in clinical study reports. Clin Chem Lab Med. 2012 Mar; 50(3):411-3. View Abstract
101. An appeal to medical journal editors: the need for a full description of laboratory methods and specimen handling in clinical study reports. Scand J Clin Lab Invest. 2012 Apr; 72(2):89-91. View Abstract
102. An appeal to medical journal editors: the need for a full description of laboratory methods and specimen handling in clinical study reports. Statement by the Consortium of Laboratory Medicine Journal Editors. Ann Clin Biochem. 2012 Mar; 49(Pt 2):105-7. View Abstract
103. An appeal to medical journal editors: the need for a full description of laboratory methods and specimen handling in clinical study reports. Clin Biochem. 2012 Feb; 45(3):185-6. View Abstract
104. An appeal to medical journal editors: the need for a full description of laboratory methods and specimen handling in clinical study reports. Clin Chem. 2012 Mar; 58(3):483-5. View Abstract
105. An appeal to medical journal editors: the need for a full description of laboratory methods and specimen handling in clinical study reports. Clin Chim Acta. 2012 Apr 11; 413(7-8):653-5. View Abstract
106. Loss-of-function and gain-of-function phenotypes of stomatocytosis mutant RhAG F65S. Am J Physiol Cell Physiol. 2011 Dec; 301(6):C1325-43. View Abstract
107. Full-disclosure in industry-sponsored laboratory medicine research studies: Statement by the Consortium of Laboratory Medicine Journal Editors. Am J Hematol. 2011 Mar; 86(3):244. View Abstract
108. The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: results of the multi-centre CHAMPS trial. Br J Haematol. 2011 Mar; 152(6):771-6. View Abstract
109. Full disclosure in industry-sponsored laboratory medicine research studies: statement by the Consortium of Laboratory Medicine Journal Editors. Ann Clin Biochem. 2011 Jan; 48(Pt 1):5-6. View Abstract
110. Functional characterization and modified rescue of novel AE1 mutation R730C associated with overhydrated cation leak stomatocytosis. Am J Physiol Cell Physiol. 2011 May; 300(5):C1034-46. View Abstract
111. Full disclosure in industry-sponsored laboratory medicine research studies: Statement by the Consortium of Laboratory Medicine Journal Editors. Clin Biochem. 2011 Feb; 44(2-3):149-50. View Abstract
112. Full disclosure in industry-sponsored laboratory medicine research studies: statement by the Consortium of Laboratory Medicine Journal Editors. Transfusion. 2012 Jun; 52(6):e15-6. View Abstract
113. Full-disclosure in industry-sponsored laboratory medicine research studies: statement by the Consortium of Laboratory Medicine Journal Editors. Scand J Clin Lab Invest. 2011 May; 71(3):177-8. View Abstract
114. Full disclosure in industry-sponsored laboratory medicine research studies: statement by the Consortium of Laboratory Medicine Journal Editors. Clin Chem. 2011 Mar; 57(3):359-60. View Abstract
115. Full-disclosure in industry-sponsored laboratory medicine research studies: statement by the Consortium of Laboratory Medicine Journal Editors. Clin Chem Lab Med. 2011 Jan; 49(1):3-4. View Abstract
116. Full-disclosure in industry-sponsored laboratory medicine research studies: statement by the Consortium of Laboratory Medicine Journal Editors. Clin Chim Acta. 2011 Mar 18; 412(7-8):491-2. View Abstract
117. In vitro genetic analysis of an erythrocyte determinant of malaria infection. J Infect Dis. 2010 Dec 01; 202(11):1722-7. View Abstract
118. Sequence variation at multiple loci influences red cell hemoglobin concentration. Blood. 2010 Dec 16; 116(25):e139-49. View Abstract
119. Automated reticulocyte counting: state of the art and clinical applications in the evaluation of erythropoiesis. Clin Chem Lab Med. 2010 Oct; 48(10):1369-80. View Abstract
120. Hypoxia activates a Ca2+-permeable cation conductance sensitive to carbon monoxide and to GsMTx-4 in human and mouse sickle erythrocytes. PLoS One. 2010 Jan 15; 5(1):e8732. View Abstract
121. Early detection of response to hydroxyurea therapy in patients with sickle cell anemia. Hemoglobin. 2010; 34(5):424-9. View Abstract
122. Chemical crosslinking studies with the mouse Kcc1 K-Cl cotransporter. Blood Cells Mol Dis. 2009 May-Jun; 42(3):233-40. View Abstract
123. An immunoassay for human serum hepcidin at last: Ganz klar? Blood. 2008 Nov 15; 112(10):3922-3. View Abstract
124. PTPepsilon has a critical role in signaling transduction pathways and phosphoprotein network topology in red cells. Proteomics. 2008 Nov; 8(22):4695-708. View Abstract
125. Use of a preoperative bleeding questionnaire in pediatric patients who undergo adenotonsillectomy. Otolaryngol Head Neck Surg. 2008 Oct; 139(4):546-550. View Abstract
126. An economic analysis of anemia prevention during infancy. J Pediatr. 2009 Jan; 154(1):44-9. View Abstract
127. Use of erythropoiesis stimulating agents and intravenous iron for cancer and treatment-related anaemia: the need for predictors and indicators of effectiveness has not abated. Br J Haematol. 2008 Jul; 142(1):3-10. View Abstract
128. Reduced DIDS-sensitive chloride conductance in Ae1-/- mouse erythrocytes. Blood Cells Mol Dis. 2008 Jul-Aug; 41(1):22-34. View Abstract
129. Protective effects of phosphodiesterase-4 (PDE-4) inhibition in the early phase of pulmonary arterial hypertension in transgenic sickle cell mice. FASEB J. 2008 Jun; 22(6):1849-60. View Abstract
130. Phase I study of magnesium pidolate in combination with hydroxycarbamide for children with sickle cell anaemia. Br J Haematol. 2008 Jan; 140(1):80-5. View Abstract
131. Foxo3 is required for the regulation of oxidative stress in erythropoiesis. J Clin Invest. 2007 Aug; 117(8):2133-44. View Abstract
132. Quantitative trait loci for peripheral blood cell counts: a study in baboons. Mamm Genome. 2007 May; 18(5):361-72. View Abstract
133. Disruption of erythroid K-Cl cotransporters alters erythrocyte volume and partially rescues erythrocyte dehydration in SAD mice. J Clin Invest. 2007 Jun; 117(6):1708-17. View Abstract
134. Reticulocyte hemoglobin equivalent (Ret He) and assessment of iron-deficient states. Clin Lab Haematol. 2006 Oct; 28(5):303-8. View Abstract
135. [Clinical trials of new therapeutic pharmacology for sickle cell disease]. Sante. 2006 Oct-Dec; 16(4):263-8. View Abstract
136. Teaching pediatric laboratory medicine to pathology residents. Arch Pathol Lab Med. 2006 Jul; 130(7):1031-8. View Abstract
137. Effect of complete protein 4.1R deficiency on ion transport properties of murine erythrocytes. Am J Physiol Cell Physiol. 2006 Nov; 291(5):C880-6. View Abstract
138. Protective effects of S-nitrosoalbumin on lung injury induced by hypoxia-reoxygenation in mouse model of sickle cell disease. Am J Physiol Lung Cell Mol Physiol. 2006 Sep; 291(3):L457-65. View Abstract
139. Quantitative trait loci for baseline erythroid traits. Mamm Genome. 2006 Apr; 17(4):298-309. View Abstract
140. Suppression of Fas-FasL coexpression by erythropoietin mediates erythroblast expansion during the erythropoietic stress response in vivo. Blood. 2006 Jul 01; 108(1):123-33. View Abstract
141. Regulation of K-Cl cotransport by protein phosphatase 1alpha in mouse erythrocytes. Pflugers Arch. 2006 Mar; 451(6):760-8. View Abstract
142. Quantitative trait loci for baseline white blood cell count, platelet count, and mean platelet volume. Mamm Genome. 2005 Oct; 16(10):749-63. View Abstract
143. Screening healthy infants for iron deficiency using reticulocyte hemoglobin content. JAMA. 2005 Aug 24; 294(8):924-30. View Abstract
144. An algorithm using reticulocyte hemoglobin content (CHr) measurement in screening adolescents for iron deficiency. J Adolesc Health. 2005 Jun; 36(6):529. View Abstract
145. Genetic influences on peripheral blood cell counts: a study in baboons. Blood. 2005 Aug 15; 106(4):1210-4. View Abstract
146. Evidence for a protective role of the Gardos channel against hemolysis in murine spherocytosis. Blood. 2005 Aug 15; 106(4):1454-9. View Abstract
147. Protein phosphatase 1alpha is tyrosine-phosphorylated and inactivated by peroxynitrite in erythrocytes through the src family kinase fgr. Free Radic Biol Med. 2005 Jun 15; 38(12):1625-36. View Abstract
148. 5-hydroxymethyl-2-furfural modifies intracellular sickle haemoglobin and inhibits sickling of red blood cells. Br J Haematol. 2005 Feb; 128(4):552-61. View Abstract
149. In vivo reduction of erythrocyte oxidant stress in a murine model of beta-thalassemia. Haematologica. 2004 Nov; 89(11):1287-98. View Abstract
150. Abnormal regulation of Mg2+ transport via Na/Mg exchanger in sickle erythrocytes. Blood. 2005 Jan 01; 105(1):382-6. View Abstract
151. Physiological roles of the intermediate conductance, Ca2+-activated potassium channel Kcnn4. J Biol Chem. 2004 Nov 12; 279(46):47681-7. View Abstract
152. Daily multivitamins with iron to prevent anemia in high-risk infants: a randomized clinical trial. Pediatrics. 2004 Jul; 114(1):86-93. View Abstract
153. Automated flow cytometric analysis of blood cells in cerebrospinal fluid: analytic performance. Am J Clin Pathol. 2004 May; 121(5):690-700. View Abstract
154. Iron therapy in the pediatric hemodialysis population. Pediatr Nephrol. 2004 Jun; 19(6):655-61. View Abstract
155. Sickle cell disease: from membrane pathophysiology to novel therapies for prevention of erythrocyte dehydration. J Pediatr Hematol Oncol. 2003 Dec; 25(12):927-33. View Abstract
156. Iron deficiency and erythropoiesis: new diagnostic approaches. Clin Chem. 2003 Oct; 49(10):1573-8. View Abstract
157. Hydroxyurea and sickle cell disease: a chance for every patient. JAMA. 2003 Apr 02; 289(13):1692-4. View Abstract
158. Preliminary assessment of inhaled nitric oxide for acute vaso-occlusive crisis in pediatric patients with sickle cell disease. JAMA. 2003 Mar 05; 289(9):1136-42. View Abstract
159. Regulation of K-Cl cotransport during reticulocyte maturation and erythrocyte aging in normal and sickle erythrocytes. Am J Physiol Cell Physiol. 2003 Jul; 285(1):C31-8. View Abstract
160. ICA-17043, a novel Gardos channel blocker, prevents sickled red blood cell dehydration in vitro and in vivo in SAD mice. Blood. 2003 Mar 15; 101(6):2412-8. View Abstract
161. A hematologic "gold standard" for iron-deficient states? Clin Chem. 2002 Jul; 48(7):981-2. View Abstract
162. Headpiece domain of dematin is required for the stability of the erythrocyte membrane. Proc Natl Acad Sci U S A. 2002 May 14; 99(10):6637-42. View Abstract
163. Developing treatment for sickle cell disease. Expert Opin Investig Drugs. 2002 May; 11(5):645-59. View Abstract
164. Pediatric laboratory medicine: current challenges and future opportunities. Am J Clin Pathol. 2002 May; 117(5):683-90. View Abstract
165. Failure of red blood cell maturation in mice with defects in the high-density lipoprotein receptor SR-BI. Blood. 2002 Mar 01; 99(5):1817-24. View Abstract
166. Modulation of Gardos channel activity by cytokines in sickle erythrocytes. Blood. 2002 Jan 01; 99(1):357-603. View Abstract
167. Pathophysiological-based approaches to treatment of sickle cell disease. Annu Rev Med. 2003; 54:89-112. View Abstract
168. Ineffective erythropoiesis in Stat5a(-/-)5b(-/-) mice due to decreased survival of early erythroblasts. Blood. 2001 Dec 01; 98(12):3261-73. View Abstract
169. Erythrocyte-active agents and treatment of sickle cell disease. Semin Hematol. 2001 Oct; 38(4):324-32. View Abstract
170. K-Cl cotransport modulation by intracellular Mg in erythrocytes from mice bred for low and high Mg levels. Am J Physiol Cell Physiol. 2001 Oct; 281(4):C1385-95. View Abstract
171. A dominant negative mutant of the KCC1 K-Cl cotransporter: both N- and C-terminal cytoplasmic domains are required for K-Cl cotransport activity. J Biol Chem. 2001 Nov 09; 276(45):41870-8. View Abstract
172. Novel therapies for prevention of erythrocyte dehydration in sickle cell anemia. Drug News Perspect. 2001 May; 14(4):208-20. View Abstract
173. Treatment with NS3623, a novel Cl-conductance blocker, ameliorates erythrocyte dehydration in transgenic SAD mice: a possible new therapeutic approach for sickle cell disease. Blood. 2001 Mar 01; 97(5):1451-7. View Abstract
174. Flow-cytometric analysis of erythrocytes and reticulocytes in congenital dyserythropoietic anaemia type II (CDA II): value in differential diagnosis with hereditary spherocytosis. Clin Lab Haematol. 2001 Feb; 23(1):7-13. View Abstract
175. Therapeutic strategies for prevention of sickle cell dehydration. Blood Cells Mol Dis. 2001 Jan-Feb; 27(1):71-80. View Abstract
176. Prevention of red cell dehydration: a possible new treatment for sickle cell disease. Pediatr Pathol Mol Med. 2001 Jan-Feb; 20(1):15-25. View Abstract
177. Reticulocyte parameters as potential discriminators of recombinant human erythropoietin abuse in elite athletes. Int J Sports Med. 2000 Oct; 21(7):471-9. View Abstract
178. Stimulation of human erythrocyte K-Cl cotransport and protein phosphatase type 2A by n-ethylmaleimide: role of intracellular Mg++. J Membr Biol. 2000 Sep 15; 177(2):159-68. View Abstract
179. Erythropoietin, iron, and erythropoiesis. Blood. 2000 Aug 01; 96(3):823-33. View Abstract
180. E2F4 is essential for normal erythrocyte maturation and neonatal viability. Mol Cell. 2000 Aug; 6(2):281-91. View Abstract
181. Structure and genetic polymorphism of the mouse KCC1 gene. Biochim Biophys Acta. 2000 Jul 24; 1492(2-3):353-61. View Abstract
182. Plasminogen activator inhibitor-1: defining characteristics in the cerebrospinal fluid of newborns. J Pediatr. 2000 Jul; 137(1):132-4. View Abstract
183. A novel method utilising markers of altered erythropoiesis for the detection of recombinant human erythropoietin abuse in athletes. Haematologica. 2000 Jun; 85(6):564-72. View Abstract
184. Maximum urine concentrating ability in children with Hb SC disease: effects of hydroxyurea. Am J Hematol. 2000 May; 64(1):47-52. View Abstract
185. Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage. Hepatology. 2000 Apr; 31(4):997-1004. View Abstract
186. Reticulocyte cellular indices: a new approach in the diagnosis of anemias and monitoring of erythropoietic function. Crit Rev Clin Lab Sci. 2000 Apr; 37(2):93-130. View Abstract
187. Positional cloning of zebrafish ferroportin1 identifies a conserved vertebrate iron exporter. Nature. 2000 Feb 17; 403(6771):776-81. View Abstract
188. Oral magnesium pidolate: effects of long-term administration in patients with sickle cell disease. Br J Haematol. 2000 Feb; 108(2):284-9. View Abstract
189. Formation of dense erythrocytes in SAD mice exposed to chronic hypoxia: evaluation of different therapeutic regimens and of a combination of oral clotrimazole and magnesium therapies. Blood. 1999 Dec 15; 94(12):4307-13. View Abstract
190. Mouse K-Cl cotransporter KCC1: cloning, mapping, pathological expression, and functional regulation. Am J Physiol. 1999 11; 277(5):C899-912. View Abstract
191. Serine/threonine protein phosphatases and regulation of K-Cl cotransport in human erythrocytes. Am J Physiol. 1999 11; 277(5):C926-36. View Abstract
192. Endothelins activate Ca(2+)-gated K(+) channels via endothelin B receptors in CD-1 mouse erythrocytes. Am J Physiol. 1999 10; 277(4):C746-54. View Abstract
193. Targeted disruption of the beta adducin gene (Add2) causes red blood cell spherocytosis in mice. Proc Natl Acad Sci U S A. 1999 Sep 14; 96(19):10717-22. View Abstract
194. Fetal anemia and apoptosis of red cell progenitors in Stat5a-/-5b-/- mice: a direct role for Stat5 in Bcl-X(L) induction. Cell. 1999 Jul 23; 98(2):181-91. View Abstract
195. Reticulocyte hemoglobin content to diagnose iron deficiency in children. JAMA. 1999 Jun 16; 281(23):2225-30. View Abstract
196. Mild spherocytosis and altered red cell ion transport in protein 4. 2-null mice. J Clin Invest. 1999 Jun; 103(11):1527-37. View Abstract
197. Structural and functional consequences of antigenic modulation of red blood cells with methoxypoly(ethylene glycol). Blood. 1999 Mar 15; 93(6):2121-7. View Abstract
198. The effect of hemoglobin A and S on the volume- and pH-dependence of K-Cl cotransport in human erythrocyte ghosts. J Membr Biol. 1999 Feb 01; 167(3):233-40. View Abstract
199. Deferiprone therapy in homozygous human beta-thalassemia removes erythrocyte membrane free iron and reduces KCl cotransport activity. J Lab Clin Med. 1999 Jan; 133(1):64-9. View Abstract
200. Novel AE1 mutations in recessive distal renal tubular acidosis. Loss-of-function is rescued by glycophorin A. J Clin Invest. 1998 Dec 15; 102(12):2173-9. View Abstract
201. Positional cloning of the zebrafish sauternes gene: a model for congenital sideroblastic anaemia. Nat Genet. 1998 Nov; 20(3):244-50. View Abstract
202. cDNA cloning and functional characterization of the mouse Ca2+-gated K+ channel, mIK1. Roles in regulatory volume decrease and erythroid differentiation. J Biol Chem. 1998 Aug 21; 273(34):21542-53. View Abstract
203. Autosomal dominant distal renal tubular acidosis is associated in three families with heterozygosity for the R589H mutation in the AE1 (band 3) Cl-/HCO3- exchanger. J Biol Chem. 1998 Mar 13; 273(11):6380-8. View Abstract
204. The effect of dietary magnesium supplementation on the cellular abnormalities of erythrocytes in patients with beta thalassemia intermedia. Haematologica. 1998 Feb; 83(2):118-25. View Abstract
205. Activated protein C concentrate for the treatment of meningococcal endotoxin shock in rabbits. Shock. 1998 Feb; 9(2):138-42. View Abstract
206. Use of reticulocyte cellular indices in the diagnosis and treatment of hematological disorders. Int J Clin Lab Res. 1998; 28(1):1-11. View Abstract
207. Clinical Applications of Automated Reticulocyte Indices. Hematology. 1998; 3(2):165-76. View Abstract
208. The antifungal antibiotic, clotrimazole, inhibits chloride secretion by human intestinal T84 cells via blockade of distinct basolateral K+ conductances. Demonstration of efficacy in intact rabbit colon and in an in vivo mouse model of cholera. J Clin Invest. 1997 Dec 15; 100(12):3111-20. View Abstract
209. Anemia in hemodialysis patients: variables affecting this outcome predictor. J Am Soc Nephrol. 1997 Dec; 8(12):1921-9. View Abstract
210. Oral magnesium supplements reduce erythrocyte dehydration in patients with sickle cell disease. J Clin Invest. 1997 Oct 01; 100(7):1847-52. View Abstract
211. Removal of erythrocyte membrane iron in vivo ameliorates the pathobiology of murine thalassemia. J Clin Invest. 1997 Sep 15; 100(6):1459-64. View Abstract
212. Low concentrations of nitric oxide increase oxygen affinity of sickle erythrocytes in vitro and in vivo. J Clin Invest. 1997 Sep 01; 100(5):1193-8. View Abstract
213. Cellular effects of hydroxyurea in Hb SC disease. Br J Haematol. 1997 Sep; 98(4):838-44. View Abstract
214. Cerebrospinal fluid plasminogen activator inhibitor-1: a prognostic factor in posthaemorrhagic hydrocephalus. Acta Paediatr. 1997 Sep; 86(9):995-8. View Abstract
215. Dietary magnesium supplementation ameliorates anemia in a mouse model of beta-thalassemia. Blood. 1997 Aug 01; 90(3):1283-90. View Abstract
216. Reticulocyte hemoglobin: an integrated parameter for evaluation of erythropoietic activity. Am J Clin Pathol. 1997 Aug; 108(2):133-42. View Abstract
217. The effect of intravenous iron on the reticulocyte response to recombinant human erythropoietin. Br J Haematol. 1997 Aug; 98(2):292-4. View Abstract
218. Inhibition of maxi-K currents in ferret portal vein smooth muscle cells by the antifungal clotrimazole. Am J Physiol. 1997 Jul; 273(1 Pt 1):C45-56. View Abstract
219. Use of recombinant human erythropoietin outside the setting of uremia. Blood. 1997 Jun 15; 89(12):4248-67. View Abstract
220. The antifungal imidazole clotrimazole and its major in vivo metabolite are potent blockers of the calcium-activated potassium channel in murine erythroleukemia cells. J Membr Biol. 1997 May 15; 157(2):177-91. View Abstract
221. Degree of agreement in plasma fibrinogen among two functional and one immunonephelometric assays. Am J Clin Pathol. 1997 May; 107(5):527-33. View Abstract
222. Erythrocyte membrane transport physiology. Curr Opin Hematol. 1997 Mar; 4(2):122-7. View Abstract
223. Characterization of adult alpha- and beta-globin genes in the zebrafish. Blood. 1997 Jan 15; 89(2):688-700. View Abstract
224. Reinterpretation of the RACTK1 K+ channel. Am J Physiol. 1997 Jan; 272(1 Pt 1):C350-4. View Abstract
225. A multiparameter analysis of sickle erythrocytes in patients undergoing hydroxyurea therapy. Blood. 1996 Dec 15; 88(12):4701-10. View Abstract
226. The antifungal antibiotic, clotrimazole, inhibits Cl- secretion by polarized monolayers of human colonic epithelial cells. J Clin Invest. 1996 Nov 01; 98(9):2066-75. View Abstract
227. Modulation of erythrocyte potassium chloride cotransport, potassium content, and density by dietary magnesium intake in transgenic SAD mouse. Blood. 1996 Oct 01; 88(7):2738-44. View Abstract
228. Anion exchanger 1 (band 3) is required to prevent erythrocyte membrane surface loss but not to form the membrane skeleton. Cell. 1996 Sep 20; 86(6):917-27. View Abstract
229. Therapy with oral clotrimazole induces inhibition of the Gardos channel and reduction of erythrocyte dehydration in patients with sickle cell disease. J Clin Invest. 1996 Mar 01; 97(5):1227-34. View Abstract
230. Resistance to osmotic lysis in BXD-31 mouse erythrocytes: association with upregulated K-Cl cotransport. Am J Physiol. 1996 Mar; 270(3 Pt 1):C866-77. View Abstract
231. Combination therapy of erythropoietin, hydroxyurea, and clotrimazole in a beta thalassemic mouse: a model for human therapy. Blood. 1996 Feb 01; 87(3):1188-95. View Abstract
232. Clotrimazole and efaroxan inhibit red cell Gardos channel independently of imidazoline I1 and I2 binding sites. Eur J Pharmacol. 1996 Jan 04; 295(1):109-12. View Abstract
233. A high-performance liquid chromatographic assay for the determination of itraconazole concentration using solid-phase extraction and small sample volume. Ther Drug Monit. 1995 Oct; 17(5):522-5. View Abstract
234. Sulfhydryl oxidation and activation of red cell K(+)-Cl- cotransport in the transgenic SAD mouse. Am J Physiol. 1995 Oct; 269(4 Pt 1):C899-906. View Abstract
235. Ca(2+)-activated K+ channels of human and rabbit erythrocytes display distinctive patterns of inhibition by venom peptide toxins. J Membr Biol. 1995 Sep; 147(1):71-82. View Abstract
236. A new therapeutic approach for sickle cell disease. Blockade of the red cell Ca(2+)-activated K+ channel by clotrimazole. Ann N Y Acad Sci. 1995 Jul 12; 763:262-71. View Abstract
237. Inhibition of red cell Ca(2+)-activated K+ transport by clotrimazole does not take place via imidazoline binding sites. Ann N Y Acad Sci. 1995 Jul 12; 763:287-9. View Abstract
238. Clotrimazole inhibits cell proliferation in vitro and in vivo. Nat Med. 1995 Jun; 1(6):534-40. View Abstract
239. Oral administration of clotrimazole and blockade of human erythrocyte Ca(++)-activated K+ channel: the imidazole ring is not required for inhibitory activity. J Pharmacol Exp Ther. 1995 Apr; 273(1):266-72. View Abstract
240. Cation transport in mouse erythrocytes: role of K(+)-Cl- cotransport in regulatory volume decrease. Am J Physiol. 1995 Apr; 268(4 Pt 1):C894-902. View Abstract
241. HPLC measurement, blood distribution, and pharmacokinetics of oral clotrimazole, potentially useful antisickling agent. Clin Chem. 1995 Mar; 41(3):387-91. View Abstract
242. Erythrocyte dehydration in pathophysiology and treatment of sickle cell disease. Curr Opin Hematol. 1995 Mar; 2(2):132-8. View Abstract
243. Mutations of conserved arginines in the membrane domain of erythroid band 3 lead to a decrease in membrane-associated band 3 and to the phenotype of hereditary spherocytosis. Blood. 1995 Feb 01; 85(3):634-40. View Abstract
244. Automated reticulocyte counting and measurement of reticulocyte cellular indices. Evaluation of the Miles H*3 blood analyzer. Am J Clin Pathol. 1994 Nov; 102(5):623-32. View Abstract
245. Oxidative damage and erythrocyte membrane transport abnormalities in thalassemias. Blood. 1994 Jul 01; 84(1):315-20. View Abstract
246. Reticulocyte hemoglobin content (CHr): early indicator of iron deficiency and response to therapy. Blood. 1994 May 15; 83(10):3100-1. View Abstract
247. Effects of subcutaneous recombinant human erythropoietin in normal subjects: development of decreased reticulocyte hemoglobin content and iron-deficient erythropoiesis. J Lab Clin Med. 1994 May; 123(5):660-7. View Abstract
248. Management training for pathology residents. I. Results of a national survey. Am J Clin Pathol. 1994 May; 101(5):559-63. View Abstract
249. Management training for pathology residents. II. Experience with a focused curriculum. Am J Clin Pathol. 1994 May; 101(5):564-8. View Abstract
250. Treatment with oral clotrimazole blocks Ca(2+)-activated K+ transport and reverses erythrocyte dehydration in transgenic SAD mice. A model for therapy of sickle cell disease. J Clin Invest. 1994 Apr; 93(4):1670-6. View Abstract
251. Efficacy of different dosing regimens for recombinant human erythropoietin in a simulated perisurgical setting: the importance of iron availability in optimizing response. Am J Med. 1994 Feb; 96(2):139-45. View Abstract
252. Duplication of 10 nucleotides in the erythroid band 3 (AE1) gene in a kindred with hereditary spherocytosis and band 3 protein deficiency (band 3PRAGUE). J Clin Invest. 1994 Jan; 93(1):121-30. View Abstract
253. Inhibition of Ca(2+)-dependent K+ transport and cell dehydration in sickle erythrocytes by clotrimazole and other imidazole derivatives. J Clin Invest. 1993 Jul; 92(1):520-6. View Abstract
254. Membrane properties of erythrocytes in subjects undergoing multiple blood donations with or without recombinant erythropoietin. Br J Haematol. 1993 May; 84(1):118-30. View Abstract
255. Ca(2+)-activated K+ transport in erythrocytes. Comparison of binding and transport inhibition by scorpion toxins. J Biol Chem. 1993 Apr 25; 268(12):8760-8. View Abstract
256. Red blood cell regeneration induced by subcutaneous recombinant erythropoietin: iron-deficient erythropoiesis in iron-replete subjects. Blood. 1993 Feb 15; 81(4):956-64. View Abstract
257. Membrane transport of Na and K and cell dehydration in sickle erythrocytes. Experientia. 1993 Feb 15; 49(2):100-9. View Abstract
258. Effect of cell age and phenylhydrazine on the cation transport properties of rabbit erythrocytes. J Cell Physiol. 1993 Feb; 154(2):271-80. View Abstract
259. Hydroxyurea and erythropoietin therapy in sickle cell anemia. Semin Oncol. 1992 Jun; 19(3 Suppl 9):74-81. View Abstract
260. Effect of irradiation on red cell cation content and transport. Transfusion. 1992 Mar-Apr; 32(3):246-52. View Abstract
261. Thawing fresh frozen plasma in a microwave oven. A comparison with thawing in a 37 degrees C waterbath. Am J Clin Pathol. 1992 Feb; 97(2):227-32. View Abstract
262. Hemoglobin variants and activity of the (K+Cl-) cotransport system in human erythrocytes. Blood. 1992 Feb 01; 79(3):793-7. View Abstract
263. [Physiopathology of erythrocyte membrane transport]. Haematologica. 1991 Jun; 76 Suppl 3:191-8. View Abstract
264. Treatment of sickle cell anemia with hydroxyurea and erythropoietin. N Engl J Med. 1990 Aug 09; 323(6):366-72. View Abstract
265. Voltage-activated cation permeability in high-potassium but not low-potassium red blood cells. Am J Physiol. 1990 Jun; 258(6 Pt 1):C1169-72. View Abstract
266. Voltage-activated cation transport in human erythrocytes. Am J Physiol. 1989 Nov; 257(5 Pt 1):C986-96. View Abstract
267. Characteristics of the volume- and chloride-dependent K transport in human erythrocytes homozygous for hemoglobin C. J Membr Biol. 1989 Oct; 111(1):69-81. View Abstract
268. Acid pH induces formation of dense cells in sickle erythrocytes. Blood. 1989 Jul; 74(1):487-95. View Abstract
269. Ca2+-activated K+ efflux limits complement-mediated lysis of human erythrocytes. J Clin Invest. 1989 May; 83(5):1466-71. View Abstract
270. Role of chloride in potassium transport through a K-Cl cotransport system in human red blood cells. Am J Physiol. 1989 May; 256(5 Pt 1):C994-1003. View Abstract
271. Ion content and transport and the regulation of volume in sickle cells. Ann N Y Acad Sci. 1989; 565:96-103. View Abstract
272. Properties of K+ transport in resealed human erythrocyte ghosts. Am J Physiol. 1988 Sep; 255(3 Pt 1):C346-56. View Abstract
273. Complement induces a transient increase in membrane permeability in unlysed erythrocytes. J Clin Invest. 1988 Aug; 82(2):594-600. View Abstract
274. Inhibition of K transport by divalent cations in sickle erythrocytes. Blood. 1987 Dec; 70(6):1810-5. View Abstract
275. The Li+-Na+ exchange and Na+-K+-Cl- cotransport systems in essential hypertension. Hypertension. 1987 Nov; 10(5 Pt 2):I4-10. View Abstract
276. Membrane polyunsaturated fatty acids and lithium-sodium countertransport in human erythrocytes. Life Sci. 1987 Aug 31; 41(9):1171-8. View Abstract
277. Properties of the Na+-K+ pump in human red cells with increased number of pump sites. J Clin Invest. 1987 Jul; 80(1):128-37. View Abstract
278. Cell volume, K transport, and cell density in human erythrocytes. Am J Physiol. 1987 Mar; 252(3 Pt 1):C269-76. View Abstract
279. Bradykinin and vasopressin stimulate Na+-K+-Cl- cotransport in cultured endothelial cells. Am J Physiol. 1986 Jun; 250(6 Pt 1):C888-95. View Abstract
280. Regulation of erythrocyte cation and water content in sickle cell anemia. Science. 1986 Apr 18; 232(4748):388-90. View Abstract
281. [Frequency and sex and age distribution of cardiopathy in arterial hypertension]. Minerva Cardioangiol. 1986 Mar; 34(3):119-25. View Abstract
282. [Incidence of retinal and renal complications in arterial hypertension]. Minerva Cardioangiol. 1986 Mar; 34(3):99-105. View Abstract
283. Modes of operation and variable stoichiometry of the furosemide- sensitive Na and K fluxes in human red cells. J Gen Physiol. 1986 Jan; 87(1):113-42. View Abstract
284. Furosemide-sensitive Na and K fluxes in human red cells. Net uphill Na extrusion and equilibrium properties. J Gen Physiol. 1986 Jan; 87(1):91-112. View Abstract
285. Regulation of cation content and cell volume in hemoglobin erythrocytes from patients with homozygous hemoglobin C disease. J Clin Invest. 1985 May; 75(5):1608-17. View Abstract
286. Elevation of red cell sodium-lithium countertransport in hyperlipidemias. Life Sci. 1985 Feb 18; 36(7):649-55. View Abstract
287. The regulation of Na-K cotransport system and essential hypertension. Klin Wochenschr. 1985; 63 Suppl 3:52-4. View Abstract
288. Effect of metabolic depletion on the furosemide-sensitive Na and K fluxes in human red cells. J Membr Biol. 1985; 86(2):145-55. View Abstract
289. Multiple arterial stenoses in chronic ergot toxicity. N Engl J Med. 1984 Jan 26; 310(4):261. View Abstract
290. Electrolyte composition and equilibrium in hemoglobin CC red blood cells. Trans Assoc Am Physicians. 1984; 97:104-12. View Abstract
291. Lithium-sodium countertransport in erythrocytes of normal and hypertensive subjects. Relationship with age and plasma renin activity. Hypertension. 1983 Jul-Aug; 5(4):529-34. View Abstract
292. [Relations between renin activity and vascular complications of arterial hypertension]. Minerva Cardioangiol. 1982 Mar; 30(3):75-80. View Abstract
293. [Multiple renal arteries and arterial hypertension: a review of 337 renal arteriography cases]. Minerva Cardioangiol. 1980 May; 28(5):289-04. View Abstract
Show All Publications Show Fewer Publications